Boehringer Ingelheim International GmbH

900 Ridgebury Road
Ridgefield,  CT  06877

United States
http://www.us.boehringer-ingelheim.com/
  • Booth: 21081

Through scientific innovation and collaboration, Boehringer Ingelheim is committed to discovering and developing novel anti-cancer agents that address unmet needs across a broad range of solid and hematological malignancies. Approved agents are for specific NSCLC sub-types and the oncology portfolio is supported by a strong early pipeline. As part of our unique research approach, we seek out strong partnerships and remain dedicated to delivering treatments that improve cancer patients’ lives.


  •  
  •      
     

  •  
  •